Methods and compositions for delivering a payload at TnMUC1 positive cancer cells. Anti-TnMUC1 CARs and transgene payloads can be engineered into immune cells so that the transgene payload is expressed and delivered at desired times from the immune cell. Such anti-TnMUC1 CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Substances and methods are dislosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Disclosed herein are serine threonine kinase (AKT) degradation/disruption compounds including an AKT ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, containing a complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof as an active ingredient. It has been confirmed that a significantly higher synergistic anticancer activity is exhibited in a case where the complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof is administered compared to a case where the biguanide-based compound or a pharmaceutically acceptable salt thereof; and the flavone, hydroxyflavone, flavanone, flavone derivative, hydroxyflavone derivative, flavanone derivative or a pharmaceutically acceptable salt thereof are each administered singly. Consequently, the pharmaceutical composition containing a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof in a complex, mixed or combined manner according to the present invention can be usefully utilized for the prevention or treatment of cancer.

The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, containing a complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof as an active ingredient. It has been confirmed that a significantly higher synergistic anticancer activity is exhibited in a case where the complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof is administered compared to a case where the biguanide-based compound or a pharmaceutically acceptable salt thereof; and the flavone, hydroxyflavone, flavanone, flavone derivative, hydroxyflavone derivative, flavanone derivative or a pharmaceutically acceptable salt thereof are each administered singly. Consequently, the pharmaceutical composition containing a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof in a complex, mixed or combined manner according to the present invention can be usefully utilized for the prevention or treatment of cancer.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.